TreeFrog Therapeutics

Frédéric Desdouits, Ph.D., CEO

April 20 | 2:15pm | Gaudi 2 Ballroom

Pessac, France


In-Person Presentation

TreeFrog Therapeutics is a biotech company aiming to provide access to safe and affordable cell therapies for millions of patients. Using proprietary C-Stem™ technology, TreeFrog Therapeutics announced in April 2021 the production of a single batch of 15 billion human induced pluripotent stem cells in a 10L bioreactor with an unprecedented expansion factor of 276-fold per week. Biomimetic C-Stem™ technology – which overcomes current bottlenecks in cell therapy manufacturing regarding scalability and costs also introduces a new quality standard for hiPSC-derived cell products, with preservation of genomic integrity at scale and ready-to-transplant hiPSC-derived 3D microtissues, for faster time to effect and improved safety. Developing a pipeline of cell therapies with mass-market potential addressing neurodegenerative disorders, cardiac, and metabolic diseases, as well as blood and immune disorders, TreeFrog Therapeutics will open a technological hub in Boston, U.S. in early 2022 to establish novel co-development partnerships.

By using this website you agree to accept our Privacy Policy and Terms & Conditions